Sinovac Biotech Ltd (SVA) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
Sinovac Biotech Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Sinovac Biotech Ltd's ROI in the fourth quarter of 2025?
Sinovac Biotech Ltd recorded a cumulative net loss of $-199 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -2.22%.
Within the Healthcare sector 263 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 2626 to 3135.
SINOVAC Biotech Ltd., a prominent biopharmaceutical company, has released its unaudited financial results for the first half of 2024. In this report, we analyze the salient features of SINOVAC’s financial performance, elucidating the implications for stakeholders, investors, and the pharmaceutical industry at large. Revenue Performance SINOVAC s revenue for the first half of 2024 demonstrated a notable increase compared to the same period in the previous year. This upsurge can be attributed to the successful commercialization of new vaccines and expanded market reach. Key products, such as the COVID-19 vaccine and various influenza vaccines, continued to contribute significantly to revenue growth. Operating Expenses and RandD Investments The financial report shed light on increased operating expenses, which were primarily driven by escalated research and development (RandD) activities. SINOVAC s commitment to innovation and development is evident from its substantial investment in RandD. These investments encompass the advancement of next-generation vaccines, diversification of the product pipeline, and enhancement of production capabilities. While such expenditures have impacted short-term profitability, they are expected to bolster long-term growth and sustain competitive advantage.
Sinovac Reports Unaudited First-Half 2024 Financial Results: A Year of Challenges and Opportunities BEIJING Sinovac Biotech Ltd. (NASDAQ: SVA), a name synonymous with biopharmaceutical excellence in China, has released its unaudited financial results for the first half of 2024. Despite facing financial headwinds, the company is taking resolute steps toward a better future and continues to serve as a pillar in the global healthcare landscape. A Look at the Financials For the six months ending June 30, 2024, Sinovac reported sales of $121.3 million, a notable decline from the $140.4 million achieved in the same period last year. This 13.6% drop in sales illustrates the adverse impacts of global economic conditions and evolving market dynamics. However, it also reflects the company s unwavering commitment to addressing these challenges head-on.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
